Experience

Vevo Therapeutics

• Biotechnology Research
• 1 - 100 Employee

• Chief Scientific Officer and Co-founder

  • Apr 2022 - Present

  San Francisco, California, United States Building the next big thing in single-cell drug discovery. Vevo Therapeutics is a biotechnology company using its in vivo drug discovery platform and next generation AI models to uncover better drugs for more patients. The company’s Mosaic platform is the first to make in vivo data generation scalable, with single-cell precision, to capture in vivo context of disease at the first step of drug discovery and to better represent patient diversity in drug response over current in vitro… Show more Building the next big thing in single-cell drug discovery. Vevo Therapeutics is a biotechnology company using its in vivo drug discovery platform and next generation AI models to uncover better drugs for more patients. The company’s Mosaic platform is the first to make in vivo data generation scalable, with single-cell precision, to capture in vivo context of disease at the first step of drug discovery and to better represent patient diversity in drug response over current in vitro assays. Vevo is using Mosaic to build the world’s largest in vivo atlas of how drugs interact with patient cells and training AI models on its data to find novel targets and drugs undetectable by other technologies. Show less



University of California, San Francisco

• United States
• Higher Education
• 700 & Above Employee

• PHD Student in Dr. Hani Goodarzi's lab

  • Jul 2016 - Apr 2022

  San Francisco Bay Area RNA Binding Proteins (RBPs) - Showed that RBMS1 acts a suppressor of metastasis by binding to its target transcripts - Cancer Discovery 2020, Publication Single Cell RNA Sequencing - Working on a method to conduct single cell multiplexed drug screening in vivo - Working on Lineage tracing methods in the context of metastasis and drug resistance



Broad Institute of MIT and Harvard

• Research Services
• 700 & Above Employee

• Research Associate II

  • Mar 2015 - May 2016

  Cambridge, MA I functional characterized the effects of GWAS derived SNPs in the context of Atrial Fibrilation, with the goal of translating basic research into tractable, drugable targets.



Biogen

• United States
• Biotechnology Research
• 700 & Above Employee

• Associate Scientist I

  • Sep 2013 - Mar 2015

  Research Triangle Park, NC Technical Development, Downstream -Ran assays quantifying product and contaminants from large scale Antibody purification processes -Utilized RT-PCR, FRET, Alphascreen, MSD, fluorescence based analytical methods -Developed automated methods using Hamilton robots